Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (DE:VX1)
XETRA:VX1
RESEARCH TOOLSreports
Holding DE:VX1?
Track your performance easily
VX1 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€353.40 - €489.20
Previous CloseN/A
Volume2.00
Average Volume (3M)170.00
Market Cap
$108.74B
Enterprise Value€116.56B
Total Cash (Recent Filing)$1.43B
Total Debt (Recent Filing)$521.34M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Feb 11, 2025EPS Estimate
3.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.95
Shares Outstanding257,529,300
10 Day Avg. Volume112
30 Day Avg. Volume170
Standard Deviation0.07
R-Squared0.00002
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.37
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue10.97
Enterprise Value/Gross Profit13.54
Enterprise Value/Ebitda255.04
Forecast
1Y Price Target
€466.66Price Target Upside11.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering26
Vertex Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Commercial ExpansionVertex is focusing on diversifying its commercial portfolio beyond cystic fibrosis, targeting areas like SCD, renal, pain, and T1D.
Market OpportunityManagement remains confident in the approval of suzetrigine with a broad label to treat patients with acute pain, seeing a multi-billion opportunity that fills the gap between anti-inflammatory/analgesics and opioids.
Pipeline InnovationVertex Pharmaceuticals presented promising results for the VX-880 study in Type 1 diabetes, with patients achieving insulin independence.
Bears Say
Clinical Trial ResultsThe data from the Ph2 study of suzetrigine in Painful Lumbosacral Radiculopathy was negative, showing no difference from placebo.
Market CompetitionEvolving competitive dynamics in the CF market, including developments by Sionna, are reasons to stay vigilant.
Sales EstimatesVertex Pharmaceuticals' projected 2035 sales for Suzetrigine have been reduced from $4 billion to $3 billion.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.17% Insiders
35.14% Mutual Funds
0.79% Other Institutional Investors
40.04% Public Companies and Individual Investors
VX1 FAQ
What was Vertex Pharmaceuticals’s price range in the past 12 months?
Vertex Pharmaceuticals lowest stock price was €353.40 and its highest was €489.20 in the past 12 months.
What is Vertex Pharmaceuticals’s market cap?
Vertex Pharmaceuticals’s market cap is $108.74B.
When is Vertex Pharmaceuticals’s upcoming earnings report date?
Vertex Pharmaceuticals’s upcoming earnings report date is Feb 11, 2025 which is in 9 days.
How were Vertex Pharmaceuticals’s earnings last quarter?
Vertex Pharmaceuticals released its earnings results on Nov 04, 2024. The company reported €4.203 earnings per share for the quarter, beating the consensus estimate of €3.913 by €0.29.
Is Vertex Pharmaceuticals overvalued?
According to Wall Street analysts Vertex Pharmaceuticals’s price is currently Undervalued.
Does Vertex Pharmaceuticals pay dividends?
Vertex Pharmaceuticals does not currently pay dividends.
What is Vertex Pharmaceuticals’s EPS estimate?
Vertex Pharmaceuticals’s EPS estimate is 3.84.
How many shares outstanding does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has 257,529,300 shares outstanding.
What happened to Vertex Pharmaceuticals’s price movement after its last earnings report?
Vertex Pharmaceuticals reported an EPS of €4.203 in its last earnings report, beating expectations of €3.913. Following the earnings report the stock price went up 4.354%.
Which hedge fund is a major shareholder of Vertex Pharmaceuticals?
Among the largest hedge funds holding Vertex Pharmaceuticals’s share is Manning & Napier Advisors LLC. It holds Vertex Pharmaceuticals’s shares valued at 72M.
---
Vertex Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€466.66 (11.02% Upside)
€466.66 (11.02% Upside)
Blogger Sentiment
Bullish
DE:VX1 Sentiment 96%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.00%
12-Months-Change
Fundamentals
Return on Equity
-2.99%
Trailing 12-Months
Asset Growth
2.37%
Trailing 12-Months
Company Description
Vertex Pharmaceuticals
Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
---
VX1 Company Deck
---
VX1 Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance and positive momentum for Vertex, with notable revenue growth, successful product launches, and significant pipeline advancements. However, challenges remain in treatment center expansion, opioid crisis costs, and regulatory complexities in specific programs.Read More>---
VX1 Revenue Breakdown
61.20% U.S.
31.50% Europe
7.29% Other
---
VX1 Stock 12 Month Forecast
Average Price Target
€466.66
▲(11.02% Upside)
Technical Analysis
Best Analysts Covering VX1
1 Year
1 Year Success Rate
25/32 ratings generated profit
1 Year Average Return
+22.43%
reiterated a buy rating 21 days ago
Copying Michael Yee's trades and holding each position for 1 Year would result in 78.13% of your transactions generating a profit, with an average return of +22.43% per trade.
---